Analysis by array CGH of genomic changes associated with the progression or relapse of Wilm's tumour

Journal of Pathology

Volumn 211, Issue 1, 2007, Pages 52-59

  Natrajan, R ^a   Little, S E ^a   Sodha, N ^b   Reis Filho, J S ^b   Mackay, A ^b   Fenwick, K ^b   Ashworth, A ^b   Perlman, E J ^c   Dome, J S ^d   Grundy, P E ^e   Pritchard Jones, K ^a   Jones, Chris ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

17p; aCGH; Anaplasia; Relapse; TP53; Wilms' tumour; WT1

Indexed keywords

GENOMIC DNA; SOMATOMEDIN C RECEPTOR; WT1 PROTEIN;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER RELAPSE; CHROMOSOME 11P; CHROMOSOME 15Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE EXPRESSION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NEPHROBLASTOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIRIDIA; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENES, P53; GENES, WILMS TUMOR; HOMOZYGOTE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; WILMS TUMOR;

EID: 33846197915     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2087     Document Type: Article

References (28)

1. Kalapurakal JA. Dome JS. Perlman EJ, Malogolowkin M, Haase GM, Grundy P, et al. Management of Wilms' tumour: current practice and future goals. Lancet Oncol 2004;5:37-46.
2. Metzger ML, Dome JS. Current therapy for Wilms' tumor. Oncologist 2005;10:815-826.
3. Beckwith JB. New developments in the pathology of Wilms' tumor. Cancer Invest 1997;15:153-162.
4. Grundy PE, Breslow NE, Li S. Perlman E, Beckwith JB, Ritchey ML, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms' tumor: a report from the national Wilms' tumor study group. J Clin Oncol 2005;23:7312-7321.
5. Hing S, Lu YJ, Summersgill B, King-Underwood L, Nicholson J, Grundy P, et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol 2001;158:393-398.
6. Lu YJ, Hing S, Williams R, Pinkerton R, Shipley J, Pritchard-Jones K. Chromosome 1q expression profiling and relapse in Wilms' tumour. Lancet 2002;360:385-386.
7. Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick K, et al. Array CGH profiling of favourable histology Wilms' tumours reveals novel gains and losses associated with relapse. J Pathol 2006;210:49-58.
8. Dome JS, Bockhold CA, Li SM, Baker SD, Green DM, Perlman EJ, et al. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor. J Clin Oncol 2005;23:9138-9145.
9. Eggert A, Grotzer MA, Ikegaki N, Zhao H, Cnaan A, Brodeur GM, et al. Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor. J Clin Oncol 2001;19:689-696.
10. Li W. Kessler P, Yeger H, Alami J, Reeve AE, Heathcott R, et al. A gene expression signature for relapse of primary Wilms' tumors. Cancer Res 2005;65:2592-2601.
11. Takahashi M, Yang XJ, Lavery TT, Furge KA, Williams BO, Tretiakova M, et al. Gene expression profiling of favorable histology Wilms' tumors and its correlation with clinical features. Cancer Res 2002;62:6598-6605.
12. Williams RD, Hing SN, Greer BT, Whiteford CC, Wei JS, Natrajan R, et al. Prognostic classification of relapsing favorable histology Wilms' tumor using cDNA microarray expression profiling and support vector machines. Genes Chromosomes Cancer 2004;41:65-79.
13. Greshock J, Naylor TL, Margolin A, Diskin S, Cleaver SH, Futreal PA, et al. 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. Genome Res 2004;14:179-187.
14. Reis-Filho JS, Simpson PT, Jones C, Steele D, Mackay A, Iravani M, et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 2005;207:1-13.
15. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15.
16. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, Tibshirani R, et al. Missing value estimation methods for DNA microarrays. Bioinformatics 2001;17:520-525.
17. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nature Genet 2001;29:365-371.
18. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, et al. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 2004:13:1303-1313.
19. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 2004;20:3413-3422.
20. Westphall PH, Young SS. Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment. John Wiley: Chichester, 1993.
21. Little SE, Hanks SP, King-Underwood L, Jones C, Rapley EA, Rahman N, et al. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study. J Clin Oncol 2004;22:4140-4146.
22. Glavac D. Dean M. Applications of heteroduplex analysis for mutation detection in disease genes. Hum Mutat 1995;6:281-287.
23. Ganguly A, Rock MJ, Prockop DJ. Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci U S A 1993;90:10325-10329.
24. Clayton-Smith J, Laan L. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003;40:87-95.
25. Stock C. Ambros IM, Lion T, Zoubek A, Amann G, Gadner H, et al. Genetic changes of two Wilms' tumors with anaplasia and a review of the literature suggesting a marker profile for therapy resistance. Cancer Genet Cytogenet 2002;135:128-138.
26. Beckwith JB, Zuppan CE, Browning NG, Moksness J, Breslow NE. Histological analysis of aggressiveness and responsiveness in Wilms' tumor. Med Pediatr Oncol 1996;27:422-428.
27. Natrajan R, Reis-Filho JS, Little SE, Messahel B, Brundler M-A, Dome JS, et al. Blastemal expression of type I insulin-like growth factor receptor in Wilms tumours is driven by increased copy number and correlates with relapse. Cancer Res (in press).
28. Huibregtse JM, Scheffner M, Howley PM. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 1993;13:775-784.